2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108868
    Mersalyl 492-18-2
    Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects.
    Mersalyl
  • HY-109567
    Gemcabene 183293-82-5 99.91%
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity.
    Gemcabene
  • HY-111614
    Melengestrol acetate 2919-66-6 99.76%
    Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity. Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research.
    Melengestrol acetate
  • HY-112388
    GSK-3b Inhibitor XI 626604-39-5 99.10%
    GSK-3b Inhibitor XI (Compound 33) is a potent and selective GSK3β inhibitor, with a Ki value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimer’s disease.
    GSK-3b Inhibitor XI
  • HY-112731
    TFAP 1011244-68-0 99.98%
    TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC50 of 0.8 μM.
    TFAP
  • HY-113239
    Hydroxycotinine 34834-67-8 ≥99.0%
    Hydroxycotinine is the main nicotine metabolite detected in smokers urine.
    Hydroxycotinine
  • HY-113268
    Biotin sulfone 40720-05-6 99.83%
    Biotin sulfone, a structural analog and metabolite of Biotin (HY-B0511), exerts competitive inhibition against Biotin in Lactobacillus arabinosus 17-5.
    Biotin sulfone
  • HY-113357
    m-Coumaric acid 588-30-7 99.96%
    m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats.
    m-Coumaric acid
  • HY-113367
    Suberylglycine 60317-54-6 99.72%
    Suberylglycine is an acyl glycine, which is a normally minor metabolite of fatty acid.
    Suberylglycine
  • HY-114134
    Epoetin beta 122312-54-3
    Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research.
    Epoetin beta
  • HY-114165
    DJ-V-159 2253744-53-3 99.94%
    DJ-V-159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
    DJ-V-159
  • HY-116474
    Viridicatol 14484-44-7 99.93%
    Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis.
    Viridicatol
  • HY-120208
    MK204 1959605-73-2 99.7%
    MK204 is an aldose reductase (AR) inhibitor that can be used in diabetes research.
    MK204
  • HY-123297
    TUG-469 1236109-67-3 99.67%
    TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes.
    TUG-469
  • HY-124113
    4'-Bromo-resveratrol 1224713-90-9 99.94%
    4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD+/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma.
    4'-Bromo-resveratrol
  • HY-124141
    Myristelaidic acid 50286-30-1 99.9%
    Myristelaidic acid (trans-9-Tetradecenoic acid), a 14-carbon trans fatty acid, is the trans isomer of Myristoleic acid. Myristelaidic acid is found in most animal fats.
    Myristelaidic acid
  • HY-124890
    Thr101 727664-79-1 99.48%
    Thr101 is an inhibitor (IC50=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia).
    Thr101
  • HY-125544
    LY 295427 152755-31-2 98.0%
    LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research.
    LY 295427
  • HY-126144
    GSK-3β inhibitor 1 187325-53-7 98.82%
    GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats.
    GSK-3β inhibitor 1
  • HY-128487
    H-​Trp-​Glu-​OH 36099-95-3 99.95%
    H-​Trp-​Glu-​OH is a selective, reversible and cell-permeable PPARγ with a Kd of ~8 µM. H-​Trp-​Glu-​OH might be developed as a possible lead compound in diabetes research.
    H-​Trp-​Glu-​OH
Cat. No. Product Name / Synonyms Application Reactivity